

**REMARKS**

Claims 127 and 129 are pending.

**A. Regarding double patenting**

The Action continues to reject claims 127 and 129 under the judicially created doctrine of obviousness-type double patenting as allegedly unpatentable over claim 1 of U.S. Pat. No. 6,426,209 B1 (the '209 patent). Applicants respectfully traverse the rejection.

Attached are terminal disclaimers from (A) InSight Strategy and Marketing Ltd. ("InSight"); and (B) Hadasit Medical Research Services and Development Ltd., the co-owners of the subject application.

Accordingly, Applicants respectfully request that this rejection be withdrawn.

**CONCLUSION**

All of the issues raised in the Office Action have been addressed and are believed to have been overcome. Therefore Applicants respectfully request a Notice of Allowance to this effect.

Respectfully submitted,

A handwritten signature in cursive script, appearing to read "Martin D. Moynihan".

Martin Moynihan,

Registration Number 40,338

Date: March 16, 2009

**Enclosure:**

- Terminal Disclaimer (regarding U.S Pat. No. 6,426,209 B1)